Current Report Filing (8-k)
May 07 2020 - 9:20AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported) May 7, 2020
Wize
Pharma, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-52545
|
|
88-0445167
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
5b
Hanagar Street, Hod Hasharon, Israel
|
|
4527708
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: +(972) 72-260-0536
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On
May 7, 2020, Wize Pharma, Inc (the “Company”) announced that it completed treating patients in its Phase IV clinical
trial of its prescription eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjogren’s
syndrome. The Company further announced that, due to the COVID-19 pandemic, the topline data from the Phase IV clinical trial
may be delayed into the third fiscal quarter of 2020.
Warning
Concerning Forward Looking Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, the Company is using forward-looking
statements when it discusses the expected release of topline data from its Phase IV clinical trial. Because such statements are
subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking
statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that
may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation,
the possibility that the Company will not be able to successfully operate its joint venture with Cannabics Pharmaceuticals, Inc.;
the Company’s needs for additional financing; the Company’s dependence on a single compound, LO2A and on the continuation
of its license to commercialize LO2A; the Company’s inability to expand its rights under its license of LO2A; the initiation,
timing, progress and results of the Company’s trials and product candidate development efforts; the Company’s ability
to advance LO2A into clinical trials or to successfully complete its preclinical studies or clinical trials; the Company’s
receipt of regulatory approvals for LO2A, and the timing of other regulatory filings and approvals; the clinical development,
commercialization and market acceptance of LO2A; the Company’s ability to establish and maintain corporate collaborations;
the implementation of its business model and strategic plans for its business and product candidates; the scope of protection
the Company is able to establish and maintain for intellectual property rights covering LO2A and its ability to operate its business
without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, and
capital requirements; competitive companies, technologies and its industry; and statements as to the impact of the political and
security situation in Israel on the Company’s business. Except as otherwise required by law, the Company undertakes no obligation
to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting
the registrant, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
Wize
Pharma, Inc.
|
|
|
|
|
By:
|
/s/
Or Eisenberg
|
|
Name:
|
Or
Eisenberg
|
Date:
May 7, 2020
|
Title:
|
Chief
Financial Officer
|
2